|  |  |  |  |
| --- | --- | --- | --- |
|  | | **Please read the checklist for submitting comments at the end of this form.** We cannot accept forms that are not filled in correctly or arrive after the deadline.  In addition to your comments below, we would like to hear your views on these questions:   1. Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline? 2. NICE would welcome your views on the currency of the CSG8 guidelines: [Improving outcomes for people with skin tumours including melanoma](https://www.nice.org.uk/guidance/csg8/evidence/full-guideline-2006-pdf-2191950685) (2006) and [The management of low-risk basal cell carcinomas in the community](https://www.nice.org.uk/guidance/csg8/resources/improving-outcomes-for-people-with-skin-tumours-including-melanoma-2010-partial-update-pdf-773380189) (2010). NICE is proposing to update the CSG8 guidance and either remove, retain or update recommendations. We would be grateful for your views on this proposal and the following related questions:  * In what way is CSG8 relevant to current practice? * Which of the recommendations in CSG8 can be removed, as they are no longer relevant, or they are established practice? * Which of the recommendations in CSG8 can be retained in current form, as there is no new evidence, but they are not yet established practice? * Which of the recommendations in CSG8 need to be updated, as there is new evidence since the previous review?   [Developing NICE guidance: how to get involved](https://www.nice.org.uk/process/pmg22/chapter/introduction) has a list of possible areas for comment on the draft scope. | |
| Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank): | | **[Insert name of organisation here]** | |
| Disclosure  Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry. | | **[Insert disclosure here]** | |
| Name of person completing form: | | **[Insert your name here]** | |
| Type | | [for office use only] | |
| **Comment**  **No.** | Page  number  or **‘general’** for comments on the whole document | **Line**  **number**  or **‘general’** for comments on the whole document | Comments Insert each comment in a new row.  Do not paste other tables into this table, as your comments could get lost – type directly into this table. |
| Example | 3 | 55 | The draft scope currently excludes people who have already been diagnosed. We feel this group should be included because…. |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 |  |  |  |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |
| 9 |  |  |  |
| 10 |  |  |  |
| 11 |  |  |  |
| 12 |  |  |  |
| 13 |  |  |  |
| 14 |  |  |  |
| 15 |  |  |  |
| 16 |  |  |  |
| 17 |  |  |  |
| 18 |  |  |  |
| 19 |  |  |  |
| 20 |  |  |  |

Please add extra rows as needed.

|  |
| --- |
| **Checklist for submitting comments:**   * Use this form and submit it as a Word document (not a PDF). * Complete the disclosure about links with, or funding from, the tobacco industry. * Include page and line number (not section number) of the text each comment is about. * Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation. * Do not paste other tables into this table – type directly into the table. * **Mark any confidential information or other material that you do not wish to be made public. Also, ensure that you state in your email to NICE that you have confidential comments included in your submission.** * Do not include medical information about yourself or another person from which you or the person could be identified. * Spell out any abbreviations you use * For copyright reasons, do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments. * **We do not accept comments submitted after the deadline stated for close of consultation.**   **Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.  Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. |